Avacta announces that it has identified three Affimer proteins capable of binding to a recombinant form of secreted Zika virus NS1 protein, which is diagnostic of Zika virus infection at the early, acute stage
Avacta and Mologic announce they have formed a collaborative partnership to develop diagnostic tests against multiple targets of clinical interest for point of care testing, using Avacta’s Affimer technology.
Report describes early progress towards Affimer biotherapeutics
Avacta Group plc announces its interim results for the period ended 31 January 2016.
Avacta announces that a range of multimeric Affimer constructs central to its immuno-oncology programme have been successfully generated and manufactured with excellent production yields in simple production systems.
Avacta is pleased to announce that it will be hosting an investor evening in London, on Thursday 5 May
Avacta is pleased to announce that it has appointed three leading immunologists to form its new Scientific Advisory Board.
Avacta has been awarded grant funding to develop and potentially commercialise novel Affimer reagents to reduce use of animals in life sciences research.
Hardman & Co have issued a research report on Avacta focusing on the group’s "revolutionary Affimer technology".